Bayer files long-acting haemophilia therapy in the US
US regulators are reviewing Bayer’s BAY94-9027, a longer-acting Factor VIII therapy designed to reduce the number of infusions necessary to prevent bleeds in patients with Haemophilia A.
Read More
